ライフサイエンスコーパス: relapsing-remitting

1 and 28 MS patients (seven men, 21 women; 18 relapsing remitting, 10 secondary progressive; mean age

2 7 healthy control subjects, 27 patients with relapsing-remitting, 23 with secondary-progressive and 2

3 with a clinically isolated syndrome, 29 with relapsing-remitting, 28 with secondary-progressive and 2

4 ars, disease duration 14.6+/-10 years; 67.8% relapsing-remitting, 28% secondary progressive and 4.2%

5 6 +/- 1.39 versus 49.13 +/- 1.19, P < 0.01), relapsing-remitting (48.86 +/- 2.89 versus 47.44 +/- 2.7

6 icipants included 36 individuals with MS (30 relapsing-remitting, 6 secondary or primary progressive)

7 Forty-three patients with relapsing remitting and 28 with secondary progressive mu

8 ith distance from the ventricles in both the relapsing remitting and secondary progressive multiple s

9 d degenerating brain and spinal cord in both relapsing-remitting and progressive forms of MS and may

10 Individuals suffering from relapsing-remitting and secondary progressive MS had sig

11 rrently being evaluated for the treatment of relapsing, remitting, and primary progressive multiple s

12 This case of relapsing-remitting AVWS demonstrates the use of VWFpp:A

13 stigated the protective role of IL-10 during relapsing-remitting bacteremia and explored the molecula

14 ain endothelial cell apoptosis occurs during relapsing-remitting bacteremia in the absence of IL-10 a

15 fected with M. amphoriforme manifesting as a relapsing-remitting bacterial load, interspersed by peri

16 em traditionally characterized by an initial relapsing-remitting clinical course and focal inflammato

17 The case is presented due to the relapsing-remitting clinical course of the disease that

18 and white matter of the CNS, resulting in a relapsing-remitting CNS autoimmunity.

19 ed syndrome (coefficient = -0.32, P = 0.03), relapsing-remitting (coefficient = -0.48, P < 0.01), sec

20 2 of 268 (94.0%) patients who maintained the relapsing-remitting course and 58 of 66 (87.8%) patients

21 tly reduced disease severity, but retain the relapsing-remitting course, a phenotype reversed by sele

22 Despite varying prior severity of relapsing-remitting course, all participants experienced

23 of distinguishing secondary progressive from relapsing remitting disease (excluding patients in clini

24 secondary progressive disease and 14 with a relapsing remitting disease course) underwent T1- and T2

25 Because atopic dermatitis (AD) is a relapsing remitting disease, assessing long-term control

26 Patients with MS with relapsing-remitting disease course or SP were included.

27 ression was more common in younger patients, relapsing-remitting disease course, and after a smaller

28 y of myelin-reactive CD4 T cells that elicit relapsing-remitting disease have not been quantified.

29 d by a global increasing incidence driven by relapsing-remitting disease in females.

30 t decisions are based on what is known about relapsing-remitting disease remains unclear.

31 In NOD mice, EAE develops as a relapsing-remitting disease that transitions to a chroni

32 AZD1480 delays disease onset of PLP-induced relapsing-remitting disease, reduces relapses and dimini

33 ry and secondary progressive disease than in relapsing-remitting disease.

34 ocyte ratio was observed in MS patients with relapsing-remitting disease.

35 nantly of younger patients and patients with relapsing-remitting disease.

36 g the first relapse in a SJL animal model of relapsing-remitting EAE abrogated clinical disease, infl

37 to study the effects of MC heterogeneity on relapsing-remitting EAE and other SJL strain-specific di

38 of Del-1-Fc ameliorated clinical relapse in relapsing-remitting EAE.

39 IL-27-conditioned DCs suppressed established relapsing-remitting EAE.

40 of immunization induced active, passive and relapsing-remitting EAE.

41 Moreover, guanabenz ameliorates relapse in relapsing-remitting experimental autoimmune encephalomye

42 d progressive, as well as PLP138-151-induced relapsing-remitting experimental autoimmune encephalomye

43 preclinically, could suppress progression of relapsing-remitting experimental autoimmune encephalomye

44 ition of system Xc(-) attenuates chronic and relapsing-remitting experimental autoimmune encephalomye

45 BE1 mutations can cause an early adult-onset relapsing-remitting form of polyglucosan body disease di

46 d on the 2010 McDonald criteria (34 with the relapsing-remitting form, 2 with clinically isolated syn

47 elopment and progression of both chronic and relapsing-remitting forms of experimental allergic encep

48 We used adoptive transfer and relapsing-remitting forms of experimental autoimmune enc

49 ges were significant in both progressive and relapsing-remitting forms of the disease and correlated

50 , whereas the classifier that differentiates relapsing-remitting from progressive MS achieved a valid

51 models of autoimmunity, type 1 diabetes and relapsing-remitting immune-mediated demyelination.

52 gans occurred in IL-10-deficient mice during relapsing-remitting infection.

53 Multiple sclerosis (MS) is a chronic relapsing-remitting inflammatory disease of the central

54 males with progressive disease compared with relapsing-remitting males (RRMS) and female MS subjects,

55 Finally, in a relapsing-remitting model of EAE in SJL mice, therapeuti

56 In a relapsing-remitting model of experimental autoimmune enc

57 se episode alleviated clinical symptoms in a relapsing-remitting model of proteolipid protein139-151-

58 e inhibitor reduced relapses of disease in a relapsing/remitting model of EAE.

59 of Gli1 improves the functional outcome in a relapsing/remitting model of experimental autoimmune enc

60 d in MS by comparing the fecal microbiota in relapsing remitting MS (RRMS) (n = 31) patients to that

61 ith secondary progressive MS [SPMS], 27 with relapsing remitting MS [RRMS]) and 30 healthy volunteers

62 pha4beta-integrin molecule, in patients with relapsing remitting MS.

63 ectroscopic imaging data in 46 patients with relapsing-remitting MS (median disease duration, 0.8 yea

64 Case series of patients with relapsing-remitting MS (n = 123) or secondary-progressiv

65 Patients with active relapsing-remitting MS (n=20) and healthy controls (n=8)

66 ion (p=0.034), and relapses in patients with relapsing-remitting MS (p=0.008) during the study.

67 expression is reduced in CD4(+) T cells from relapsing-remitting MS (RR-MS) patients during relapse.

68 Patients with relapsing-remitting MS (RRMS) or clinically isolated syn

69 ethylenediaminetetraacetic acid plasma in 10 relapsing-remitting MS (RRMS) patients, 9 secondary prog

70 secondary-progressive MS (SPMS) patients, 12 relapsing-remitting MS (RRMS) patients, and 14 matched h

71 majority of plaques in acute monophasic and relapsing-remitting MS (RRMS) were active.

72 odic relapses followed by remissions, called relapsing-remitting MS (RRMS).

73 inically isolated syndrome (CIS) and 69 with relapsing-remitting MS (RRMS; mean age: CIS: 31.4 +/- 9.

74 in progressive MS (r = 0.67; p < 0.001) than relapsing-remitting MS (RRMS; r = 0.33; p = 0.007).

75 atic carriers of HTLV-1 (AC), 47 HAM/TSP, 74 relapsing-remitting MS [RRMS], 17 secondary progressive

76 Fifty-seven patients, 41 (72%) with relapsing-remitting MS and 16 (28%) with secondary-progr

77 In a prospective study, 326 patients with relapsing-remitting MS and 163 patients with progressive

78 Eighteen patients with relapsing-remitting MS and 17 healthy controls were cogn

79 Twenty-five patients with relapsing-remitting MS and 20 healthy control subjects u

80 Forty-eight patients with relapsing-remitting MS and 24 control subjects underwent

81 ODOLOGY/PRINCIPAL FINDINGS: 34 patients with relapsing-remitting MS and 24 healthy age-matched contro

82 Fifty-seven consecutive patients with relapsing-remitting MS and 30 healthy, age-matched contr

83 Twenty-six patients with relapsing-remitting MS and 32 healthy control subjects f

84 One hundred patients with relapsing-remitting MS and 50 healthy controls.

85 diagnosis of clinically isolated syndrome or relapsing-remitting MS and a minimum of 7 years of prosp

86 sability Status Scale score of 3.5 to 6.5 or relapsing-remitting MS and an Expanded Disability Status

87 nce images were acquired from 133 women with relapsing-remitting MS and analyzed using voxel-based mo

88 healthy subjects and patients diagnosed with relapsing-remitting MS and clinically isolated syndrome.

89 eters to explain IPS and EF in patients with relapsing-remitting MS and confirms the central role of

90 mean age 33.4 yrs) with clinically definite, relapsing-remitting MS and mild disability (EDSS - Expan

91 written informed consent, six patients with relapsing-remitting MS and six healthy control subjects

92 atients with clinically isolated syndrome or relapsing-remitting MS at baseline.

93 Whereas results were similar for relapsing-remitting MS cases (RRMS), those developing pr

94 ognitive performance of 99 clinically stable relapsing-remitting MS for whom data from four consequen

95 onal cohort study included 312 patients with relapsing-remitting MS in 2 independent cohorts (72 pati

96 alpha4 integrin, is effective against active relapsing-remitting MS in adults.

97 eased in patients with clinically definitive relapsing-remitting MS in comparison with healthy contro

98 t study, 14 healthy control participants, 18 relapsing-remitting MS multiple sclerosis ( RRMS relaxin

99 plifiable viral sequence was found in either relapsing-remitting MS or other neurological diseases pa

100 e measured in CD14+ monocytes from untreated relapsing-remitting MS patients and compared to healthy

101 ssessed in a training set of 334 consecutive relapsing-remitting MS patients and in an independent va

102 Sixty-six (19.7%) relapsing-remitting MS patients changed their clinical c

103 volume suitably explains the probability of relapsing-remitting MS patients evolving into the progre

104 to analyze data from a large cohort of 1,697 relapsing-remitting MS patients in British Columbia, Can

105 Ten relapsing-remitting MS patients were studied using the T

106 Relapsing-remitting MS patients who developed PML under

107 s and in an independent validation set of 84 relapsing-remitting MS patients.

108 lation between MRI changes and disability in relapsing-remitting MS patients.

109 Sixteen patients with relapsing-remitting MS subjected to 26 ART treatment cyc

110 Patients with relapsing-remitting MS treated with interferon beta (n =

111 Data on 201 pregnant women with relapsing-remitting MS were collected prospectively from

112 the phase 2 studies) and diagnosed as having relapsing-remitting MS were eligible to participate in t

113 18-60 years in phase 2 study) diagnosed with relapsing-remitting MS were included.

114 Women with relapsing-remitting MS were more anxious than men with t

115 Additionally, patients with relapsing-remitting MS were treated with narrowband UVB

116 Participants included patients with relapsing-remitting MS who were switching therapy to fin

117 creased in peripheral blood of patients with relapsing-remitting MS with a high disease score.

118 6 with clinically isolated syndrome, 42 with relapsing-remitting MS) and 23 control subjects underwen

119 onset (clinically isolated syndrome [CIS] or relapsing-remitting MS) and were also compared to two ot

120 Among patients with relapsing-remitting MS, administration of interferon bet

121 010 McDonald criteria identify children with relapsing-remitting MS, although caution is suggested wh

122 summarise emerging injectable therapies for relapsing-remitting MS, and discuss pharmacological mech

123 either clinically isolated syndrome (CIS) or relapsing-remitting MS, as well as for 15 age- and sex-m

124 age, shorter durations of MS, female gender, relapsing-remitting MS, higher educational attainment an

125 Among patients with relapsing-remitting MS, nonmyeloablative hematopoietic s

126 However, relapsing-remitting MS, which is modeled in SJL mice, is

127 play a role in the inflammatory response in relapsing-remitting MS.

128 n at the same doses shown to be effective in relapsing-remitting MS.

129 ognitive decline in a group of subjects with relapsing-remitting MS.

130 ar to that noted in a trial in patients with relapsing-remitting MS.

131 cal efficacy of these drugs in patients with relapsing-remitting MS.

132 al-appearing white matter volume (P=.005) in relapsing-remitting MS.

133 udy in participants with clinically definite relapsing-remitting MS.

134 irst-line agents for use in the treatment of relapsing-remitting MS.

135 ormed dynamic contrast-enhanced (DCE) MRI in relapsing-remitting MS.

136 d with worsening of disease in patients with relapsing-remitting MS.

137 174 relapsing-remitting MS/CIS patients were included in thi

138 inical trial of simvastatin in patients with relapsing remitting multiple sclerosis (RR MS), which de

139 ntegrity of processing of structural RNAs in relapsing remitting multiple sclerosis (RRMS) and other

140 Foxp3(+) T cells in untreated subjects with relapsing remitting multiple sclerosis (RRMS) as compare

141 rom the cerebrospinal fluid of patients with relapsing remitting multiple sclerosis (RRMS) have highe

142 progressive multiple sclerosis compared with relapsing remitting multiple sclerosis group, and these

143 Serum IL-21 from 141 individuals with relapsing remitting multiple sclerosis was measured usin

144 Thirty-nine patients with relapsing remitting multiple sclerosis, at high risk of

145 s, and more so in secondary progressive than relapsing remitting multiple sclerosis, tissue structura

146 lications for the diagnosis and treatment of relapsing remitting multiple sclerosis.

147 ins the most widely prescribed treatment for relapsing remitting multiple sclerosis.

148 ormalities between secondary progressive and relapsing remitting multiple sclerosis.

149 t approved oral therapy for the treatment of relapsing remitting multiple sclerosis.

150 and efficacy of amiselimod in patients with relapsing- remitting multiple sclerosis.

151 3 years disease duration), 18 subjects with relapsing-remitting multiple sclerosis (>/= 4 years dise

152 -progressive (49.3 +/- 8.0 mM) compared with relapsing-remitting multiple sclerosis (43.0 +/- 8.5 mM,

153 Patients with relapsing-remitting multiple sclerosis (age 18-65 years,

154 rimary and secondary-progressive compared to relapsing-remitting multiple sclerosis (coefficients = -

155 atients with clinically isolated syndrome or relapsing-remitting multiple sclerosis (Expanded Disabil

156 Hematopoietic Cell Transplantation for Relapsing-Remitting Multiple Sclerosis (HALT-MS) is an o

157 Available treatment options for relapsing-remitting multiple sclerosis (MS) have expande

158 immunomodulatory agent for the treatment of relapsing-remitting multiple sclerosis (MS) in the Unite

159 The use of natalizumab for highly active relapsing-remitting multiple sclerosis (MS) is influence

160 Unexpectedly, progressive and relapsing-remitting multiple sclerosis (MS) patients hav

161 on medications and disease progression among relapsing-remitting multiple sclerosis (MS) patients in

162 Patients who develop relapsing-remitting multiple sclerosis (MS) present with

163 No current therapy for relapsing-remitting multiple sclerosis (MS) results in s

164 uperior efficacy over interferon beta-1a for relapsing-remitting multiple sclerosis (MS), and is curr

165 acetate therapy on B cells in patients with relapsing-remitting multiple sclerosis (MS).

166 n placebo-controlled phase II/III studies of relapsing-remitting multiple sclerosis (MS).

167 r the past 15 years as a primary therapy for relapsing-remitting multiple sclerosis (MS).

168 ical and MRI activity in adult patients with relapsing-remitting multiple sclerosis (MS).

169 ts with clinically isolated syndrome (n=74), relapsing-remitting multiple sclerosis (n=664), or progr

170 is a first-line immunomodulatory therapy for relapsing-remitting multiple sclerosis (RR MS).

171 ger-type lesion' in an independent cohort of relapsing-remitting multiple sclerosis (RRMS) and AQP4-a

172 TCR stimulation is impaired in subjects with relapsing-remitting multiple sclerosis (RRMS) because of

173 umab is a newly licensed treatment of active relapsing-remitting multiple sclerosis (RRMS) in Europe,

174 The mechanism of IFN-beta therapy in relapsing-remitting multiple sclerosis (RRMS) is not wel

175 mbulatory function in disabled subjects with relapsing-remitting multiple sclerosis (RRMS) or seconda

176 e total circulating exosome transcriptome in relapsing-remitting multiple sclerosis (RRMS) patients a

177 e previously showed that memory B cells from relapsing-remitting multiple sclerosis (RRMS) patients e

178 Many JC virus antibody-positive relapsing-remitting multiple sclerosis (RRMS) patients w

179 Even within the relapsing-remitting multiple sclerosis (RRMS) population

180 osis Orally (CLARITY) study in patients with relapsing-remitting multiple sclerosis (RRMS) showed tha

181 study (the CAMMS223 study) in patients with relapsing-remitting multiple sclerosis (RRMS), alemtuzum

182 le SclerOsis (ALLEGRO), a phase III study in relapsing-remitting multiple sclerosis (RRMS), oral laqu

183 In a 12-month phase 3 study in patients with relapsing-remitting multiple sclerosis (RRMS), TRANSFORM

184 cetate (GA) are widely used in patients with relapsing-remitting multiple sclerosis (RRMS).

185 factors with long-term clinical outcomes in relapsing-remitting multiple sclerosis (RRMS).

186 odulator, for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS).

187 ta has been used as a first-line therapy for relapsing-remitting multiple sclerosis (RRMS).

188 long-lasting disease activity suppression in relapsing-remitting multiple sclerosis (RRMS).

189 a is the treatment most often prescribed for relapsing-remitting multiple sclerosis (RRMS).

190 ental autoimmune encephalomyelitis (EAE) and relapsing-remitting multiple sclerosis (RRMS).

191 Participants were patients with relapsing-remitting multiple sclerosis 18 to 55 years ol

192 l trials (Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis [AFFIRM], Safety

193 ion With Interferon Beta-1a in Patients With Relapsing-Remitting Multiple Sclerosis [SENTINEL], and I

194 al, we enrolled adults aged 18-55 years with relapsing-remitting multiple sclerosis and at least one

195 resonance imaging at 3 T in 17 patients with relapsing-remitting multiple sclerosis and in 13 normal

196 atents for the first approved treatments for relapsing-remitting multiple sclerosis are expiring, cre

197 their effects on disability in patients with relapsing-remitting multiple sclerosis are maintained an

198 ratio values in the outer cord were lower in relapsing-remitting multiple sclerosis compared with cli

199 DMTs by comparing a cohort of patients with relapsing-remitting multiple sclerosis enrolled in the U

200 ed cohort study, we identified patients with relapsing-remitting multiple sclerosis experiencing rela

201 trial, patients aged 18-60 years with active relapsing-remitting multiple sclerosis from 84 centres i

202 In 140 eyes from 70 patients having relapsing-remitting multiple sclerosis from January 2011

203 d data from propensity-matched patients with relapsing-remitting multiple sclerosis from the MSBase a

204 In the clinically isolated syndrome and relapsing-remitting multiple sclerosis groups, outer cor

205 tive disease-modifying treatments (DMTs) for relapsing-remitting multiple sclerosis have been license

206 at have regulatory approval for treatment of relapsing-remitting multiple sclerosis have little or no

207 igher in secondary-progressive compared with relapsing-remitting multiple sclerosis in cortical grey

208 tissue sodium concentration in patients with relapsing-remitting multiple sclerosis might reflect cha

209 nd extra-cellular sodium concentration in 19 relapsing-remitting multiple sclerosis patients and 17 h

210 xonal analysis could define axonal damage in relapsing-remitting multiple sclerosis patients earlier

211 nd 4-6 and 18-26 mo Tecfidera-treated stable relapsing-remitting multiple sclerosis patients using mu

212 312 on MRI Lesion Given Once Daily) Study in relapsing-remitting multiple sclerosis provides evidence

213 disagreement among devices in patients with relapsing-remitting multiple sclerosis regarding the ON

214 a T cell receptor (TCR) from a patient with relapsing-remitting multiple sclerosis that engages its

215 , phase 3 study involving 1841 patients with relapsing-remitting multiple sclerosis to compare dacliz

216 olimod, and interferon beta in patients with relapsing-remitting multiple sclerosis treated for up to

217 A total of 1106 patients with relapsing-remitting multiple sclerosis were randomly ass

218 Women aged 18-50 years with relapsing-remitting multiple sclerosis were randomly ass

219 autoimmune encephalomyelitis (EAE) model of relapsing-remitting multiple sclerosis when administered

220 udy, we randomly assigned 1292 patients with relapsing-remitting multiple sclerosis who had a recent

221 The drug might be an effective treatment for relapsing-remitting multiple sclerosis with less frequen

222 Treatment of early relapsing-remitting multiple sclerosis with the lymphocy

223 trial of annual alemtuzumab for treatment of relapsing-remitting multiple sclerosis, 6 of 216 patient

224 ggestive of CNS demyelination and typical of relapsing-remitting multiple sclerosis, a complete neuro

225 atients with first-line treatment-refractory relapsing-remitting multiple sclerosis, alemtuzumab coul

226 Eligible patients were aged 18-55 years, had relapsing-remitting multiple sclerosis, and had complete

227 fluid samples of patients with encephalitis, relapsing-remitting multiple sclerosis, and other neurol

228 ears old) with clinically isolated syndrome, relapsing-remitting multiple sclerosis, and progressive

229 In patients with relapsing-remitting multiple sclerosis, BG-12 (at both d

230 In patients with relapsing-remitting multiple sclerosis, both BG-12 regim

231 ging has been examined in small cohorts with relapsing-remitting multiple sclerosis, but has not been

232 than interferon beta-1a in the treatment of relapsing-remitting multiple sclerosis, but its efficacy

233 Among patients with relapsing-remitting multiple sclerosis, daclizumab HYP s

234 lusion criteria were a diagnosis of definite relapsing-remitting multiple sclerosis, exposure to one

235 As treatment for relapsing-remitting multiple sclerosis, glatiramer aceta

236 IFN-beta, an effective therapy against relapsing-remitting multiple sclerosis, is naturally sec

237 ns is the underlying pathological process in relapsing-remitting multiple sclerosis, the gradual accu

238 In patients with relapsing-remitting multiple sclerosis, treatment with a

239 ) is in development as an oral treatment for relapsing-remitting multiple sclerosis, which is commonl

240 a woman in her late 30s with a diagnosis of relapsing-remitting multiple sclerosis, who continued to

241 ligible patients-those aged 18-55 years with relapsing-remitting multiple sclerosis-to receive fingol

242 lockade on Treg homeostasis in patients with relapsing-remitting multiple sclerosis.

243 erapy approved for treatment of relapsing or relapsing-remitting multiple sclerosis.

244 ing agent in the management of patients with relapsing-remitting multiple sclerosis.

245 al effects on relapse rates in patients with relapsing-remitting multiple sclerosis.

246 the ADVANCE trial, a study of patients with relapsing-remitting multiple sclerosis.

247 al and MRI disease activity in patients with relapsing-remitting multiple sclerosis.

248 ort further assessment of daclizumab HYP for relapsing-remitting multiple sclerosis.

249 mmunomodulator approved for the treatment of relapsing-remitting multiple sclerosis.

250 ephalomyelitis (EAE) that mirror chronic and relapsing-remitting multiple sclerosis.

251 more efficacious than either agent alone in relapsing-remitting multiple sclerosis.

252 rug Administration approved for treatment of relapsing-remitting multiple sclerosis.

253 response to interferon beta in patients with relapsing-remitting multiple sclerosis.

254 od reduces disease activity in patients with relapsing-remitting multiple sclerosis.

255 rolled phase 3 study involving patients with relapsing-remitting multiple sclerosis.

256 ebo-controlled study involving patients with relapsing-remitting multiple sclerosis.

257 y, as compared with placebo in patients with relapsing-remitting multiple sclerosis.

258 s aged 18-50 years with previously untreated relapsing-remitting multiple sclerosis.

259 trial of previously untreated patients with relapsing-remitting multiple sclerosis.

260 tivity in previously untreated patients with relapsing-remitting multiple sclerosis.

261 reduced the rate of relapse in patients with relapsing-remitting multiple sclerosis.

262 in a Phase I/IIa clinical trial in new-onset relapsing-remitting multiple sclerosis.

263 -course oral tablet therapy in patients with relapsing-remitting multiple sclerosis.

264 s highly effective in the treatment of early relapsing-remitting multiple sclerosis.

265 negative prognostic factor in patients with relapsing-remitting multiple sclerosis.

266 rferon beta-1a (IFNbeta-1a) in patients with relapsing-remitting multiple sclerosis.

267 d for the treatment of people suffering from relapsing-remitting multiple sclerosis.

268 the first mAb approved for the treatment of relapsing-remitting multiple sclerosis.

269 milar effects on annualised relapse rates in relapsing-remitting multiple sclerosis.

270 s use for patients with previously untreated relapsing-remitting multiple sclerosis; however, benefit

271 ation due to adverse events in patients with relapsing-remitting multiple sclerosis?

272 ation reflected behaviour in the subgroup of relapsing remitting patients (rho = 0.74, P = 0.008).

273 ctions of white matter lesion enlargement in relapsing remitting patients and is associated with grea

274 ve MS patients are immunologically closer to relapsing-remitting patients as compared with patients w

275 cretion in urine samples from a cohort of 70 relapsing-remitting patients with MS who were followed f

276 is implicated as a key therapeutic target in relapsing-remitting patients.

277 tacks nor of relapses experienced during the relapsing-remitting phase after the second year up to on

278 In contrast, neither total number of relapsing-remitting phase attacks nor of relapses experi

279 However, duration of the relapsing-remitting phase did not influence the times fr

280 ar to be separated by a watershed within the relapsing-remitting phase, just a few years after clinic

281 ent disease-modifying agents for its initial relapsing-remitting phase, these therapies show limited

282 ned these measures in the pre-progressive or relapsing-remitting phase.

283 et of progression; and (v) during the entire relapsing-remitting phase.

284 e with a clinically isolated syndrome (CIS), relapsing remitting (RR) and secondary progressive (SP)

285 Among 806 patients with relapsing remitting (RR) onset MS from the London Ontari

286 We investigated this in people with relapsing-remitting (RR) and secondary progressive (SP)

287 ate neuroinflammation at different phases of relapsing-remitting (RR) experimental autoimmune encepha

288 Cho) at 3.0 T were mapped in the brain of 10 relapsing-remitting (RR) MS patients of 0.3-12 years dis

289 raphically matched normal controls (NC), and relapsing-remitting (RR) MS patients, also matched with

290 copy, we analysed the lipoprotein profile of relapsing-remitting (RR) MS patients, progressive MS pat

291 ive (PP) MS while the other three focused on relapsing-remitting (RR) MS.

292 Most patients with relapsing-remitting (RR) multiple sclerosis (MS) who rec

293 raction (PPI) analysis from 17 patients with relapsing-remitting (RR), 17 with benign, and 23 with se

294 rations were measured by ELISA in cases with relapsing-remitting (RR)-MS (n=81), secondary progressiv

295 still possible, and even favored, in stable relapsing-remitting (RR-MS) patients, whereas it was abs

296 e measured in 440 patients with MS (311 with relapsing-remitting [RR] MS, 92 with secondary-progressi

297 he article presents a case of a patient with relapsing-remitting severe BBE.

298 re aged 42-83 years and were referred with a relapsing remitting syndrome of fever (94%), constitutio

299 nical course of multiple sclerosis (MS) from relapsing-remitting to secondary progressive have not be

300 ohort of 18 MS patients (9 progressive and 9 relapsing-remitting) was compared to healthy controls an